Future antihypertensive therapies, such as centrally acting imidazoline agonists, should aim to minimize metabolic and central nervous system side effects while improving coronary artery disease outcomes.
Metabolic neutrality should guide antihypertensive selection in comorbid patients; leaves open whether imidazoline agonists warrant prospective trials.
Background A wide range of drug classes, frequently including centrally acting agents, has been used in clinical trials in hypertension which have shown benefit. Although therapy has clearly limited the complications of hypertension, further improvement is needed, especially concerning coronary artery disease. Perspectives Future interest therefore centres on drugs that do not worsen diabetes mellitus, do not cause dyslipidaemia, or induce potassium loss, while not provoking drowsiness, depression, other troublesome side-effects, or being associated with rebound hypertension when stopped. The centrally acting imidazoline agonists merit detailed study in this regard.
No takes yet. Share an insight, caveat, or question.
J. Ian S. Robertson (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: